Applied Materials, Inc. is an American corporation that supplies equipment, services and software for the manufacture of semiconductor chips for electronics, flat panel displays for computers, smartphones, televisions, and solar products.
Algen, a venture-backed preclinical stage biotech company, is using CRISPR to uncover disease-driving RNA messages to find treatments for cancer and diseases with high unmet needs. Originated from UC Berkeley, Algen’s research group focuses on developing and applying novel functional genomics technologies to address scientific challenges in drug discovery and deliver innovative, patient-centric medicines for the toughest-to-treat diseases.
AcuraStem is a preclinical-stage company focused on neurodegenerative diseases. It is advancing novel therapeutic approaches for ALS and FTD using patient-derived stem cell models. AcuraStem has developed the iNeuroRx platform, which utilizes human iPSC-derived cells to mimic neuromuscular and neurodegenerative neuron diseases such as ALS and FTD.
Apeximmune Therapeutics is a pre-clinical stage biotechnology company that is harnessing the power of the immune system to treat human disease. Based in Burlingame, CA, Apeximmune discovers and pioneers novel therapeutic antibodies that modulate immune cell activity to elicit durable, lasting efficacy in cancer and autoimmune disease. Our team integrates expertise in immunology, tumor cell biology, and protein biochemistry and engineering to provide therapies that can transform patients’ lives. We currently have several therapeutic antibody assets in various stages of preclinical development, with the aim to complete our initial IND package in the coming year.
Chain Reaction is engineering the future of disruptive blockchain and privacy technologies.
We accelerate compute performance, enabling companies to adopt and scale solutions to the world’s most complex problems.
Products:
EL3CTRUM is our Blockchain product line, starting with the most efficient hashing ASIC on the market, optimized for high-performance, high efficiency, and low-power, and is the heart of our hashboards and systems. EL3CTRUM delivers optimal payback time.
3PU™ is our Privacy product, dramatically accelerating real-time operations of Privacy Enhancing Technologies on encrypted data, transforming the cloud into a trusted environment, and enabling new verticals to adopt the cloud at scale, including financial institutions, healthcare & big pharma, defense & government, oil & gas, and more.
Purpose-built and custom-designed, our solutions power the next generation of secure, scalable, green computing to help protect people, privacy, and the planet.
Mission
To radically accelerate complex technological solutions for blockchain and privacy technologies.
Vision
To empower data centers and cloud providers to adopt scalable technologies that protect people, privacy, and the planet.
Coastar Therapeutics introduces a groundbreaking gene delivery platform poised to revolutionize cell and gene therapy. This innovative bioengineered cell membrane platform leverages the cell membrane as a Trojan horse, cloaking biological drugs to enhance efficacy and facilitate repeated dosing. The platform, showcased in a YouTube video (link: https://youtu.be/g-wfibqLOY8), amalgamates the strengths of LNP and exosomes.
Cellentia is a biotech startup committing to fight against metastatic cancers. We have a unique technology for culturing circulating tumor cells from solid tumors for doing drug screening and monitoring acquired resistance to cancer treatments. We use this technology to help drug developers identify the best cancer drugs against metastatic cancers and also do our own in-house drug discovery.
CancerFree Biotech develops 3D tumor organoid culture systems from patient blood samples, using these organoids to test cancer therapeutics. Our proprietary technology serves as a precision medicine tool for creating personalized treatment plans and is also used in drug development research to evaluate drug efficacy. CancerFree Biotech is incorporated in Delaware and operates a subsidiary in Taiwan, with offices in both New York City and Taipei.
Delta, founded in 1971, is a global provider of power and thermal management solutions. Its mission statement, "To provide innovative, clean and energy-efficient solutions for a better tomorrow," focuses on addressing key environmental issues such as global climate change. As an energy-saving solutions provider with core competencies in power electronics and automation, Delta's business categories include Power Electronics, Mobility, Automation, and Infrastructure.
Delta offers some of the most energy efficient power products in the industry, including switching power supplies with efficiency over 90%, telecom power with up to 98%, and PV inverters with up to 99.2% efficiency. We have also developed the world‘s first server power supply certified as 80 Plus Titanium.
Headquartered in Taiwan, we regularly invest over 8% of our annual sales revenues in R&D and have worldwide R&D facilities in China, Europe, Japan, Singapore, Thailand, and the U.S.
Delta is a frequent recipient of international awards and related recognition for innovation, design, and continuous dedication to ESG. Since 2011, Delta has been listed on the DJSI World Index of Dow Jones Sustainability™ Indices for 13 consecutive years. Delta has also won CDP with double A List for 3 times for its substantial contribution to climate change and water security issues and named Supplier Engagement Leader for its continuous development of a sustainable value chain for 7 consecutive years.
In response to the challenge of climate change, Delta will remain committed to the research and development of innovative, energy-saving products, solutions and services that contributing substantially to the sustainable development of mankind.
Eos BioInnovation incubates and invests in projects in the field of regenerative medicine (e.g., cell & gene therapy, tissue engineering & biomaterials, molecules promoting endogenous regeneration mechanisms or helping to stop or reverse the body's degeneration processes and enabling technologies along the value chain that accelerate regenerative medicine applications) primarily from the Harvard and Boston biotech ecosystem, as well as from other top academic and research institutions.
We are financially supported by our primary institutional partner, Panacea Venture, a $600M+ investment firm focused on healthcare investments. We have already made two investments from the Harvard network (a neuromodulation startup from Boston Children’s Hospital and a T cell reconstitution company from Mass General Hospital/Paulson School of Engineering & Applied Science) and one investment from the University of California San Francisco (an early stage senolytics startup leveraging novel immune approaches to address age-related diseases to improve human health span). We continue to look for exciting early stage biotech projects and are particularly interested in company formation opportunities where we launch promising companies with leading scientists and motivated entrepreneurs.
Fujitsu is one of the world's largest IT services providers and has a significant presence in Japan (No.1) and globally (No. 9). The company is known for its supercomputers, servers, and other high-performance computing solutions. Fujitsu also offers a wide range of enterprise software, cloud services, and cybersecurity solutions.
Throughout its history, Fujitsu has been involved in various technological innovations and has contributed to global electronics and computing industries. The company continues to focus on digital transformation and emerging technologies like artificial intelligence and the Internet of Things.
Fujitsu Research of America plays a crucial role in Fujitsu's global research and development efforts, focusing on creating innovative solutions for the North American market and contributing to Fujitsu's worldwide technological advancements.
Instant NanoBiosensors (INB) is an innovative life sciences company that has developed next generation, cost-effective ultra-sensitive real-time immunoassay platforms that advance precision health for life sciences research and diagnostics. Our platform , Light Sensing Biomarker Analyzer, based on patented FOPPR (Fiber Optic Particle Plasmon Resonance) and IN-Chip (auto-flowing microfluidic chip) technologies with 35+ global patents ( US, UK, Europe, China, Japan and Taiwan) for the life science research and in vitro diagnostics markets enables customers to reliably detect protein biomarkers in extremely low concentrations (5 orders) in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies, and also allows researchers to define and validate the function of novel protein biomarkers that are only present in very low concentrations and have been discovered using technologies such as mass spectrometry or other capital instrument . The business opportunity includes co-development, method technology transfer, technology licensing, and IVD applications. We hope to build more strategic partnership with international associates to achieve the mission of FOPPR inside.
We are executing a multinational innovation program, called as “UREKA GlobalStars Taiwan digital industrial collaborations”, in partnership with Centre for Process Innovation (CPI), a British technology and innovation social enterprise, for the purpose of enabling UK industrial digital companies to access, collaborate with and find new markets in Taiwan. Meanwhile, we are in collaboration with global research institutes including Stanford medical center, Brigham and Women's Hospital, Amsterdam UMC, New Castle and University College London in healthcare field. This can help us to provide the information of third-party verification of our technology to pharmaceutical companies so that we can accumulate our capability abundantly for future out-licensing transaction.
).png){kind=logo}
Founded in 2003, Workshop of Photonics (WOP) is a leading provider of femtosecond laser micromachining solutions for both industrial and scientific sectors worldwide. With over 20 years of continuous research and innovation, WOP delivers end-to-end services, from feasibility studies and rapid prototyping to high-precision micromachining services and fully customized femtosecond laser workstations.
WOP specializes in:
Ultrashort Pulse Laser Technologies for high-precision industrial manufacturing.
Laser micromachining solutions for industries including Semiconductor, Biotech, Automotive, Medical Devices, and Optical Communications.
Tailored femtosecond laser workstations for:
Glass, sapphire, and silicon wafer micromachining (dicing, drilling, structuring)
Fiber Bragg Grating (FBG) inscription
Waveguide writing
Custom materials and applications.
With a strong foundation of scientific excellence — backed by numerous research articles, patents, and deep theoretical and practical knowledge — WOP is not only following but actively shaping trends in ultrashort pulse laser technology.
WOP has been actively expanding its presence in Taiwan, building connections with integrators, end-users, and trading companies. We are enthusiastic about participating in the X-Talent Program, as it represents a valuable opportunity to strengthen the ties between Lithuania and Taiwan, and foster deeper collaboration in precision engineering and laser technology.
Established in 2015, Kneron is a leading provider of full stack edge AI solutions based in San Diego. Kneron was the winner of Tengfei Award by Tencent and won the third place in Innovation Competition of International Talents, Silicon Valley Division.We are dedicated to the development of integrated edge AI hardware and software solutions for vehicle, security, and broader AIoT use cases. Our mission is to empower the proliferation of accessible, low-latency, and secure AI applications by creating networks of independently intelligent devices as enabled through full stack Kneron solutions.
LIGHTEL — Empowering the Future of Fiber Optics
Since 1999, LIGHTEL has been a trusted global partner in the fiber optics and photonics industries. From our roots in developing Coupler Workstations for Fused Biconic Taper (FBT) production, we have grown into a leading provider of cutting-edge fiber optic components and inspection solutions. Our portfolio includes Fused Fiber and Micro-Optic passive components, advanced Video Microscopes, and a wide range of solutions serving the Optical Communications, Fiber Laser, and Space Laser Communication sectors.
Located in the Greater Seattle area, LIGHTEL is driving the next wave of innovation with a strong focus on high-power (kW-class) fiber laser technologies. Our advanced solutions are tailored to meet the evolving needs of Industry 4.0, Intelligent Manufacturing Systems (IMS), and Autonomous Vehicle applications.
With decades of expertise and a passion for innovation, LIGHTEL is committed to helping industries worldwide achieve faster, smarter, and more reliable optical solutions.
MSS USA CORP, established in May 2024, is a subsidiary of MSSCORPS CO., LTD. We uphold our parent company’s tradition of delivering precise and prompt analytic services with exceptional quality to clients in the semiconductor industry, positioning ourselves as the premier R&D partner in this sector.
Our core service is Transmission Electron Microscopy (TEM) analysis, which provides comprehensive structural (TEM/STEM imaging modes), chemical (EDS), and dimensional (auto CD measurements) information on materials of interest. Leveraging our proprietary and patented sample protection strategy, along with advanced FIB sample preparation techniques, we offer accurate TEM analysis for both hard and fragile materials used in cutting-edge technology developments, such as low-k dielectrics and EUV photoresists. This specialized analytic method furnishes R&D engineers with crucial insights, accelerating their development processes.
We recognize that the protection of proprietary information (PIP) is of utmost importance. MSS USA adheres to the same rigorous PIP control procedures as its parent company, which has earned the trust and recognition of numerous world-renowned semiconductor companies. Every piece of information, including provided materials, samples, data, and analytic history, is meticulously recorded, securely stored, and robustly protected. MSS USA remains a trusted R&D metrology partner for companies that prioritize the safeguarding of their proprietary information.
By expanding into the US market, we bring our expertise closer to our clients, enhancing collaboration and fostering innovation across the semiconductor industry.
Mucker Capital started about 10 years ago and has grown from an accelerator to cover everything from pre-seed to series A investments, including Honey (acquired by PayPal for $4B), ServiceTitan (last valued at $9.5B), and Emailage (acquired by LexisNexis parent RELX for $500M). As one of the top early-stage venture Capital firms in the US, Mucker's portfolio companies have raised a total $8 billion in additional outside funding.
Onyx Healthcare USA, a key subsidiary of the ASUS Computer Group, is dedicated to advancing healthcare through cutting-edge, medically certified computing solutions. With over 15 years of expertise in embedded technology and medical-grade design, Onyx empowers the healthcare industry with high-performance, fanless computing platforms engineered to meet the most demanding clinical environments.
From the operating room to bedside care, Onyx delivers a comprehensive portfolio of UL/EN60601-1 and ISO13485-certified solutions, including:
Surgical Workstations
Slim Medical Fanless Panel PCs
Medical Tablet PCs
Bedside Infotainment Terminals
Embedded Motherboards
Customized OEM/ODM Solutions
Onyx Healthcare seamlessly integrates design, manufacturing, and innovation to optimize workflows across surgery suites, nursing stations, patient wards, ambulatory care, and hospital management. Our systems are purpose-built to meet global regulatory standards (CE, FCC Class B, CSA), ensuring safety, reliability, and longevity.
Powered by the technological legacy of the ASUS Group and a commitment to innovation, Onyx Healthcare USA is shaping the future of Healthcare IT and Medical OEM — enabling next-generation smart hospitals worldwide.
At PathCision Medicine, we are redefining precision medicine by uncovering novel therapeutic targets hidden in tissue pathology. As a Boston-based biopharma startup, we are tackling some of the most pressing challenges in oncology and beyond, developing first-in-class therapies for metastatic cancer and other diseases with high unmet needs.
Our proprietary AI-powered spatial biology platform deciphers complex interactions between diseases and the tissue microenvironment. By integrating tissue pathology with advanced patient multi-omics, we generate insights that lead to clinically actionable and translatable drug candidates.
Our lead asset, a first-in-mechanism antibody-drug conjugate (ADC), selectively targets tumors while sparing healthy tissues — improving both efficacy and safety.
We are now building Version 2 of our discovery engine — a next-generation machine learning platform that will push the boundaries of AI in drug discovery. We're looking for passionate and innovative machine learning engineers to join us in this mission.
If you are excited about applying AI to solve real-world biological problems, impacting patient lives, and growing with a fast-moving biotech startup — PathCision is the place for you.
PharmaEssentia Corporation is a rapidly growing biopharmaceutical company dedicated to transforming the treatment landscape for patients with challenging diseases in hematology and oncology. By combining deep scientific expertise with proven biological principles, we are delivering innovative therapies — including one approved product and a robust, diversifying pipeline. We are committed to improving both health outcomes and quality of life for patients worldwide.
Founded in 2003 by a team of Taiwanese-American executives and leading scientists from top U.S. biotechnology and pharmaceutical companies, PharmaEssentia has since grown into a global biopharma innovator. We are publicly listed on the Taipei Exchange (TPEx: 6446) and operate across key regions including the United States, Japan, China, and Korea. Our biologics are manufactured in a state-of-the-art GMP-certified production facility in Taichung, Taiwan.
In 2022, PharmaEssentia established the PharmaEssentia Innovation Research Center (PIRC) in the Greater Boston Area — one of the world's most vibrant biotech hubs. Fully funded by PharmaEssentia, PIRC is home to a world-class drug discovery team led by industry veterans recruited from leading pharmaceutical companies such as Sanofi, Pfizer, Merck, AbbVie, and Eisai. As PIRC continues to grow, it serves as a vital engine for accelerating our innovation in biologics and expanding our global footprint.
At Polaris Electro-Optics, Inc., we believe that overcoming society’s greatest challenges requires mastery of the creation, movement, and use of information. We are mastering the movement of information by leveraging patented material and design innovations to offer the highest-speed, most energy efficient integrated photonics products to the communications and computation industries. Our goal is to define the standard for moving information. We work hard in a collaborative, cross-functional team environment, and value mutual trust and respect built on a foundation of integrity, transparency, consistency, and humility. Additional information about Polaris is available at www.PolarisEO.com.
Taboola is an AI-powered discovery platform serving over 600 million daily active users and delivering more than 450 billion personalized recommendations every month across the open web. Our mission is to help people discover content, products, and experiences they’ll love — when they are most likely to engage.
At the core of Taboola's platform is a sophisticated machine learning recommendation engine that processes massive-scale data in real time. Every second, our AI analyzes hundreds of signals — including user behavior, content semantics, contextual information, and collaborative trends — to optimize the match between users and content. This system continuously learns and adapts, ensuring relevant and high-quality recommendations across websites, devices, and mobile applications.
Our platform powers discovery for the world’s top publishers and digital properties, such as Yahoo, CNBC, BBC, NBC News, Business Insider, and The Independent. Taboola also drives e-commerce recommendations, enabling over 1 million monthly transactions for major brands like Walmart, Macy’s, Skechers, and eBay.
Founded in 2006 and listed on NASDAQ (TBLA), Taboola is headquartered in New York City with a global footprint, including R&D in Tel Aviv, Los Angeles, Hungary, and Taipei. Our team of engineers, data scientists, and AI researchers tackle some of the most exciting challenges in real-time large-scale recommendation systems, AI-driven personalization, and online monetization.
Join us as we push the boundaries of AI at scale and shape the future of discovery on the open web.
At Tachyum, we are building what others said was impossible — the world's first Universal Processor, Prodigy™, designed to power AI, HPC, and Cloud workloads beyond anything on the market.
Prodigy unifies CPU, GPU, and AI accelerator capabilities into a single chip, delivering:
3x performance boost over existing processors.
Up to 10x lower power consumption, solving one of the biggest pain points in modern data centers.
A fully homogeneous architecture, eliminating the need for separate GPUs or TPUs.
The ability to dynamically switch between cloud services and AI workloads — running data centers 24/7 at peak utilization.
This is not just about performance — it's about redefining the future of computing. Prodigy is designed to scale AI supercomputers to a level faster than the human brain, enabling a new era for deep learning, scientific computing, and hyperscale infrastructure.
By joining Tachyum, you will work directly on:
AI workloads at scale — powering the world's largest AI supercomputers.
Advanced compiler and system-level optimizations to unify traditional and AI workloads.
Next-gen chip architecture, breaking the boundaries between CPU, GPU, and AI accelerators.
Energy-efficient computing, solving global challenges in power consumption and sustainability.
Founders & technical leaders with deep roots at Nvidia, AMD, Intel, Skyera, and SandForce.
Hands-on opportunity to build a global-scale AI platform from silicon to system.
Collaborate with engineering teams across Silicon Valley, Slovakia, Czech Republic, and Las Vegas.
Direct impact on the future of AI and HPC infrastructure, solving real-world challenges in compute, power, and scalability.
Tachyum is not just another chip company — we are shaping the next generation of AI and cloud infrastructure. If you are passionate about large-scale systems, AI performance, hardware-software co-design, and solving problems that truly matter — we want you on our team.
Vizuro is an innovator and solution provider of Multimodal, Causal GenAI with its powerful applications in diverse sectors. We utilize our proprietary self-learning, explainable and actionable AI on a managed, data-science-as-a-service platform to quickly deploy bespoke applications in an expedited timeframe. We serve global clients in various sectors and sizes, ranging from Fortune 100 enterprises to startups
Founded in 1993, WI Harper Group is a pioneer and leading cross-border venture capital firm investing in early and expansion stage companies globally. With offices in San Francisco, Beijing and Taipei, the firm actively oversees more than $1 billion in assets under management. Since inception nearly three decades ago, WI Harper has invested in over 400 startups and has successfully experienced more than 100 IPO and M&A exits. We look for innovative companies and visionary founders in technology, healthcare and sustainability fields where there are high synergies and meaningful value-added cross selling opportunities. The WI Harper team will strive to work with partners to accelerate innovation and drive technology to change the world.